drugset / Trial / NCT04324489
DAS181 for Severe COVID-19: Compassionate Use
NaSingle-groupOpen-labelTreatment
Summary
The objective of the study is to investigate the safety and potential efficacy of DAS181 for the treatment of severe COVID-19.
Timeline
- Start
- 2020-03-06
- Primary completion
- 2020-04-16
- Completion
- 2020-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DAS181 | Protein / enzyme biologic | 4.5 mg | Inhaled |